Additionally, activated TGF-β signaling, as well as increased M2 macrophage infiltration, also contributes to the negative influence of these immune checkpoints on the tumor immune microenvironment to further impede the response to immunotherapy [39, 40]. This evidence concerns the gene TGFB1 and neoplasm.